Qingdao Donghai Pharmaceutical Co., Ltd. is located in Qingdao West Coast New Area. It is a high-tech enterprise specializing in the research, development, and production of innovative microecological drugs, and owns China's first National-Local Joint Engineering Research Center for Medical Microecological Products. It is also the first national demonstration project base for microecological drug industrialization supported by the National Development and Reform Commission, a national intellectual property advantage enterprise, and has a post-doctoral research station. Over the past two decades, Qingdao Donghai Pharmaceutical has been dedicated to the research, development, and production of human microecological drugs (products), and has successively won support from 4 national key new products, 4 national high-tech products, and 2 national Torch Program projects. To date, it has applied for over 70 invention patents for new microecological drugs, with 21 authorized, including 2 US invention patents for new microecological drugs. It has led and completed 5 microecological drug projects under the National High-Tech R&D Program (863 Program), developed one-third of China's total microecological drugs, and fully industrialized all of them. It has also taken the lead in formulating national standards for 6 microecological drugs. Microecological drugs launched and sold on the market, such as Atining and Bao Le'an, have relieved millions of patients, including Academician Yuan Longping, the father of hybrid rice, from the pain of irritable bowel syndrome and chronic diarrhea triggered by cold exposure, alcohol consumption, or spicy hotpot, earning high recognition from Academician Yuan Longping and numerous patients and experts. The company has also won the First Prize of Qingdao Technical Invention Award and the First Prize of Shandong Provincial Science and Technology Progress Award. In 2019, Donghai Pharmaceutical obtained 18 million yuan in funding support from Shandong Province's major new drug creation and development project. It is currently conducting research and development on multiple Class 1.1 new drugs, including anti-tumor drugs, and has already received default permission for clinical research on a Class 1.1 new drug. It is a leader in the field of microecological medicine in China.
What does Qingdao Donghai Pharmaceutical Co., Ltd. require? Who is Qingdao Donghai Pharmaceutical Co., Ltd. hiring? recruitment: 客户服务类占比最多占30.3%，其次是计算机/网络/技术类占26.4%. What education can get in at ? 本科占比最多占53.2%，其次是大专占20.9%. High education required at ? 硕士占11.9%，博士占3.5%. Work experience required at ? 不限占比最多占52.7%，其次是1-3年占28.9%. Where are the job locations at ? 青岛占比最多占100%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
